Evidence map›Paper›PMID 41890835›Full record

ArticleResearch square2026

Recurrent parasitemias with artemisinin partial resistance mutations during the 2024 Ethiopia malaria resurgence: a case series.

Dessalegn Geleta, Bokretsion G Brhane, Adugna Abera, Mahlet Belachew, Heven Sime, Atsbeha Gebreegziaxher, Melak Getu, Abraham Ali, Neamin Tesfaye, Medhanye Habtetsion and 12 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Dessalegn GeletaEthiopian Public Health Institute.
Bokretsion G BrhaneEthiopian Public Health Institute.
Adugna AberaEthiopian Public Health Institute.
Mahlet BelachewEthiopian Public Health Institute.
Heven SimeEthiopian Public Health Institute.
Atsbeha GebreegziaxherEthiopian Public Health Institute.
Melak GetuEthiopian Public Health Institute.
Abraham AliEthiopian Public Health Institute.
Neamin TesfayeEthiopian Public Health Institute.
Medhanye HabtetsionEthiopian Public Health Institute.
Belayneh KokobeEthiopian Public Health Institute.
Mandefro KebedeEthiopian Public Health Institute.
Zemene WorkuEthiopian Public Health Institute.
Geremew TasewEthiopian Public Health Institute.
Gemechu TadesseEthiopian Public Health Institute.
Getachew TolleraEthiopian Public Health Institute.
Abebe A FolaBrown University.
Jeffrey A BaileyBrown University.
Jonathan J JulianoInstitute for Global Health and Infectious Diseases.
Jonathan B ParrInstitute for Global Health and Infectious Diseases.
Melkamu AbteEthiopian Public Health Institute.
Ashenafi AssefaEthiopian Public Health Institute.

Funding

Epidemiology and determinants of emerging artemisinin-resistant malaria in EthiopiaR01AI177791 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jonathan Boyd Parr · 2023 to 2026
$3.2M
NIAID NIH HHS R01 AI177791
6 · The paper itself

Abstract

Background: Ethiopia experienced a marked resurgence of malaria in 2024. Artemisinin-based combination therapies (ACTs) are first-line treatment for uncomplicated Methods and material: We used the national Public Health Emergency Management (PHEM) surveillance system to characterize malaria resurgence and further investigate antimalarial drug resistance markers among cases of recurrent clinical malaria in three selected resurgence sites in central Ethiopia. Results: Parasite isolates from 15 patients with confirmed clinical recurrent Conclusion: The current study documents cases of recurrent parasitemia caused by

Indexed as

ACT-resistanceART-REthiopiaMalariaPfSMARRTer

Identifiers

PMID41890835
PMCPMC13015592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.